Genmab — Oktober 2018
-
9:05..However, resistance of cancer cells to CDC is a major problem.
Two FDA-approved CD20 IgG1 mAbs, rituximab and ofatumumab,
promote only ∼15 and 50% CDC, respectively, of B cells from
patients with chronic lymphocytic leukemia (CLL)...we report that hexamerization-enhanced mAbs, specific for CD20
or CD37, induced 95–99% CDC of CLL B cells at concentrations of
10–16 g/mL in samples from 20 patients. CD37 mAbs without the
E430G mutation did not mediate CDC... -
Daratumumab in myeloma update: expanding indications, Niels van de Donk @ ESH - https://www.youtube.com/watch?v=66TVQeKcp38
-
Update on recent smoldering multiple myeloma trials, Maria-Victoria Mateos @ESH https://www.youtube.com/watch?v=sF_fmbhnc0s
-
CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079 https://www.youtube.com/watch?v=8-oiXhcegjw
-
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma https://www.youtube.com/watch?v=2dwYLNTA19s
-
ja det er imponerende
-
og vi ved at Pollux er endnu bedre
-
og 43% CR i 1.Relaps er det også mere end fint
-
sorry 43
-
Tusinde tak for link Bulder. http://www.proinvestor.com/index.php?p=debat_1&postid=76324
-
Sorry E L. Right now I'm behind the counter in my shop in Rødovre Centrum. I am very busy and only look on the computer screen for a short while. I hope you can forgive me.
-
Nyt stof: Daratutumab lovende mod Amyloidosis
https://www.youtube.com/watch?v=vTdWOZ5zCM8 -
Det er vist ikke nyt?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind